Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives
- 1.3k Downloads
Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs. These side effects negatively impact therapeutic outcomes and delay subsequent cycles of chemotherapy, resulting in dose reductions and treatment discontinuation. Here, we aimed to review the experimental evidence regarding possible new targets for the management of irinotecan- and 5-FU-related intestinal mucositis.
A literature search was performed using the PubMed and MEDLINE databases. No publication time limit was set for article inclusion.
Here, we found that clinical management of intestinal mucositis and diarrhea is somewhat ineffective at reducing symptoms, possibly due to a lack of specific targets for modulation. We observed that IL-1β contributes to the apoptosis of enterocytes in mucositis induced by 5-FU. However, 5-FU-related mucositis is far less thoroughly investigated with regard to specific molecular targets when compared to irinotecan-related disease. Several studies have proposed that a correlation exists between the intestinal microbiota, the enterohepatic recirculation of active metabolites of irinotecan, and the establishment of mucositis. However, as reviewed here, this association seems to be controversial. In addition, the pathogenesis of irinotecan-induced mucositis appears to be orchestrated by interleukin-1/Toll-like receptor family members, leading to epithelial cell apoptosis.
IL-1β, IL-18, and IL-33 and the receptors IL-1R, IL-18R, ST2, and TLR-2 are potential therapeutic targets that can be modulated to minimize anticancer agent-associated toxicity, optimize cancer treatment dosing, and improve clinical outcomes. In this context, the pathogenesis of mucositis caused by other anticancer agents should be further investigated.
KeywordsCancer chemotherapy Irinotecan Inflammation Intestine Mucositis Cytokines Toll-like receptors
Inflammasome adaptor protein apoptosis-associated speck-like protein containing CARD
Chemokine (C–C motif) Ligand
Chemokine (C–X–C motif) ligand
Chemokine (C–X–C Motif) receptor
Damage-associated molecular pattern
Irinotecan with fluorouracil and folinic acid
Interleukin-1 receptor antagonist
Inducible nitric oxide synthase
Irinotecan and oxaliplatin
Myeloid differentiation primary response gene 88
Dihydronicotinamide adenine dinucleotide phosphate
Nuclear factor kappa B
Pathogen-associated molecular pattern
Reactive oxygen species
7-Ethyl-10-hydroxycamptothecin or the active metabolite of irinotecan
SN-38 glucuronide form
Toll/IL-1 receptor domain
Tumor necrosis factor-α
UDP glucuronosyltransferase 1 family, polypeptide A1
This review is dedicated to the loving memory of Prof. Dr. Ronaldo Albuquerque Ribeiro (in memoriam). R. C. P. Lima-Júnior received a research Grant from CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), Grant Nos.: 307143/2014-7 and 458872/2014-8. This work was also supported by Grants from CAPES (Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Grant CAPES-PROEX 2862/2013) and FUNCAP (Fundação Cearense de Apoio ao Desenvolvimento Científico, Grant PRONEX PR2-0101-00054.01.00/15).
RA. Ribeiro, C.W.S. Wanderley, D.V.T. Wong, J.M.S.C. Mota, C.A.V.G. Leite, M.H.L.P. Souza, F.Q. Cunha, and R.C.P. Lima-Júnior all contributed to the literature searching and reviewing and to the writing of the manuscript. C.A.V.G. Leite and C.W.S. Wanderley constructed the illustration and table, respectively. C.W.S. Wanderley, D.V.T. Wong, J.M.S.C. Mota, C.A.V.G. Leite, M.H.L.P. Souza, F.Q. Cunha, and R.C.P. Lima-Júnior approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 1.Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al (2007) Mucositis study section of the multinational association of supportive care in cancer and the international society for oral oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRefGoogle Scholar
- 5.Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Mucositis study section of the multinational association for supportive care in cancer; international society for oral oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046PubMedCrossRefGoogle Scholar
- 6.U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.03, June 2010, National Institutes of Health, National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 22 Oct 2015
- 21.Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697–702PubMedCrossRefGoogle Scholar
- 27.Hecht R (1998) Gastrointestinal toxicity of irinotecan. Oncology 12:73–78Google Scholar
- 28.Lima-Júnior RCP, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA et al (2012) Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 69:931–942PubMedCrossRefGoogle Scholar
- 32.Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E et al (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280–286PubMedCrossRefGoogle Scholar
- 58.Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J (2007) Synergism of toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 247:72–84PubMedCrossRefGoogle Scholar
- 69.Ribeiro RA, Lima-Junior RC, Leite CAV, Mota JMS, Macedo FY, Lima MV et al (2012) Chemotherapy-induced hemorrhagic cystitis: pathogenesis, pharmacological approaches and new insights. J Exp Integr Med 2:95–112Google Scholar
- 73.Leitão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Silva JV et al (2011) Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC Gastroenterol 16:11–90Google Scholar
- 75.Krishnamurthi SS Enterotoxicity of chemotherapeutic agents. UPTODATE. [Online] www.uptodate.com/contents/enterotoxicity-of-chemotherapeutic-agents. Accessed 20 Oct 2015
- 77.Ychou M, Douillard JY, Rougier P, Adenis A, Mousseau M, Dufour P et al (2000) Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am J Clin Oncol 23:143–148PubMedCrossRefGoogle Scholar
- 78.Karthaus M, Ballo H, Abenhardt W, Steinmetz T, Geer T, Schimke J et al (2005) Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 68:326–332PubMedCrossRefGoogle Scholar
- 83.Ibhanesebhor O Review of the role of loperamide and codeine in the management of symptomatic diarrhoea in adults. [Online] http://www.who.int/selection_medicines/committees/expert/18/applications/LoperamideCodeine.pdf. Accessed 20 July 2015
- 85.Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Greek Colorectal Cooperative Oncology Group. et al (2002) Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 25:65–70PubMedCrossRefGoogle Scholar
- 86.Sun L, Coy DH (2014) Somatostatin and its analogs. Curr Drug Targets. [Epub ahead of print]Google Scholar
- 91.Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J et al (2007) Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med 232:96–106Google Scholar
- 93.Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A (2003) Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805–806PubMedCrossRefGoogle Scholar
- 98.Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S et al (2014) Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis—current evidence and potential clinical applications. Aliment Pharmacol Ther 40:409–421PubMedGoogle Scholar